Cargando…

Canaloplasty and Trabeculotomy with the OMNI System in Patients with Open-Angle Glaucoma: Two-Year Results from the ROMEO Study

PURPOSE: To provide extended safety and effectiveness follow-up for eyes treated with circumferential canaloplasty and trabeculotomy (CP+TR) that were included in the 12-month ROMEO study. SETTING: Seven multi-subspecialty ophthalmology practices located in 6 states (Arkansas, California, Kansas, Lo...

Descripción completa

Detalles Bibliográficos
Autores principales: Williamson, Blake K, Vold, Steven D, Campbell, Anita, Hirsch, Louis, Selvadurai, Deepan, Aminlari, Ardalan E, Cotliar, Jeremy, Dickerson, Jaime E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086214/
https://www.ncbi.nlm.nih.gov/pubmed/37056792
http://dx.doi.org/10.2147/OPTH.S407918
_version_ 1785022100547829760
author Williamson, Blake K
Vold, Steven D
Campbell, Anita
Hirsch, Louis
Selvadurai, Deepan
Aminlari, Ardalan E
Cotliar, Jeremy
Dickerson, Jaime E
author_facet Williamson, Blake K
Vold, Steven D
Campbell, Anita
Hirsch, Louis
Selvadurai, Deepan
Aminlari, Ardalan E
Cotliar, Jeremy
Dickerson, Jaime E
author_sort Williamson, Blake K
collection PubMed
description PURPOSE: To provide extended safety and effectiveness follow-up for eyes treated with circumferential canaloplasty and trabeculotomy (CP+TR) that were included in the 12-month ROMEO study. SETTING: Seven multi-subspecialty ophthalmology practices located in 6 states (Arkansas, California, Kansas, Louisiana, Missouri, and New York). DESIGN: Retrospective, multicenter, IRB approved. SUBJECTS: Eligible eyes had mild–moderate glaucoma and were treated with CP+TR with cataract surgery or as a standalone intervention. METHODS: Main outcome measures were mean IOP, mean number of ocular hypotensive medications, mean change in number of medications, proportion of patients with a ≥20% reduction in IOP or with IOP ≤18 mmHg, and proportion of patients medication free. Safety outcomes were adverse events and secondary surgical interventions (SSI). RESULTS: Eight surgeons at 7 centers contributed 72 patients stratified by pre-operative intraocular pressure (IOP); >18 mmHg (Grp1), ≤18 mmHg (Grp2). Mean follow-up of 2.1 years (min 1.4, max 3.5). 2-year IOP (SD) was 15.6 mmHg (−6.1 mmHg, −28% from baseline) on 1.4 medications (−0.9, −39%) for Grp1 with cataract surgery; 14.7 mmHg (−7.4 mmHg, −33% from baseline) on 1.6 medications (−0.7, −15%) for Grp1 standalone, 13.7 mmHg (−0.6 mmHg, −4.2%) on 1.2 medications (−0.8, −35%) for Grp2 with cataract surgery, 13.3 mmHg (−2.3 mmHg, −14.7%) on 1.2 medications (−1.0, −46%) for Grp2 standalone. The proportion of patients at 2 years with either a ≥20% IOP reduction or IOP between 6 and 18 mmHg and no increase in medication or SSI was 75% (54 of 72, 95% CI 69.9%, 80.1%). One-third of patients (24 of 72) were medication free whereas 9 of 72 were pre-surgical. No device-related adverse events during extended follow-up; 6 eyes (8.3%) required additional surgical or laser intervention for IOP control after 12 months. CONCLUSION: CP+TR provides effective IOP control that is sustained for 2 years or more.
format Online
Article
Text
id pubmed-10086214
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-100862142023-04-12 Canaloplasty and Trabeculotomy with the OMNI System in Patients with Open-Angle Glaucoma: Two-Year Results from the ROMEO Study Williamson, Blake K Vold, Steven D Campbell, Anita Hirsch, Louis Selvadurai, Deepan Aminlari, Ardalan E Cotliar, Jeremy Dickerson, Jaime E Clin Ophthalmol Original Research PURPOSE: To provide extended safety and effectiveness follow-up for eyes treated with circumferential canaloplasty and trabeculotomy (CP+TR) that were included in the 12-month ROMEO study. SETTING: Seven multi-subspecialty ophthalmology practices located in 6 states (Arkansas, California, Kansas, Louisiana, Missouri, and New York). DESIGN: Retrospective, multicenter, IRB approved. SUBJECTS: Eligible eyes had mild–moderate glaucoma and were treated with CP+TR with cataract surgery or as a standalone intervention. METHODS: Main outcome measures were mean IOP, mean number of ocular hypotensive medications, mean change in number of medications, proportion of patients with a ≥20% reduction in IOP or with IOP ≤18 mmHg, and proportion of patients medication free. Safety outcomes were adverse events and secondary surgical interventions (SSI). RESULTS: Eight surgeons at 7 centers contributed 72 patients stratified by pre-operative intraocular pressure (IOP); >18 mmHg (Grp1), ≤18 mmHg (Grp2). Mean follow-up of 2.1 years (min 1.4, max 3.5). 2-year IOP (SD) was 15.6 mmHg (−6.1 mmHg, −28% from baseline) on 1.4 medications (−0.9, −39%) for Grp1 with cataract surgery; 14.7 mmHg (−7.4 mmHg, −33% from baseline) on 1.6 medications (−0.7, −15%) for Grp1 standalone, 13.7 mmHg (−0.6 mmHg, −4.2%) on 1.2 medications (−0.8, −35%) for Grp2 with cataract surgery, 13.3 mmHg (−2.3 mmHg, −14.7%) on 1.2 medications (−1.0, −46%) for Grp2 standalone. The proportion of patients at 2 years with either a ≥20% IOP reduction or IOP between 6 and 18 mmHg and no increase in medication or SSI was 75% (54 of 72, 95% CI 69.9%, 80.1%). One-third of patients (24 of 72) were medication free whereas 9 of 72 were pre-surgical. No device-related adverse events during extended follow-up; 6 eyes (8.3%) required additional surgical or laser intervention for IOP control after 12 months. CONCLUSION: CP+TR provides effective IOP control that is sustained for 2 years or more. Dove 2023-04-06 /pmc/articles/PMC10086214/ /pubmed/37056792 http://dx.doi.org/10.2147/OPTH.S407918 Text en © 2023 Williamson et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Williamson, Blake K
Vold, Steven D
Campbell, Anita
Hirsch, Louis
Selvadurai, Deepan
Aminlari, Ardalan E
Cotliar, Jeremy
Dickerson, Jaime E
Canaloplasty and Trabeculotomy with the OMNI System in Patients with Open-Angle Glaucoma: Two-Year Results from the ROMEO Study
title Canaloplasty and Trabeculotomy with the OMNI System in Patients with Open-Angle Glaucoma: Two-Year Results from the ROMEO Study
title_full Canaloplasty and Trabeculotomy with the OMNI System in Patients with Open-Angle Glaucoma: Two-Year Results from the ROMEO Study
title_fullStr Canaloplasty and Trabeculotomy with the OMNI System in Patients with Open-Angle Glaucoma: Two-Year Results from the ROMEO Study
title_full_unstemmed Canaloplasty and Trabeculotomy with the OMNI System in Patients with Open-Angle Glaucoma: Two-Year Results from the ROMEO Study
title_short Canaloplasty and Trabeculotomy with the OMNI System in Patients with Open-Angle Glaucoma: Two-Year Results from the ROMEO Study
title_sort canaloplasty and trabeculotomy with the omni system in patients with open-angle glaucoma: two-year results from the romeo study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086214/
https://www.ncbi.nlm.nih.gov/pubmed/37056792
http://dx.doi.org/10.2147/OPTH.S407918
work_keys_str_mv AT williamsonblakek canaloplastyandtrabeculotomywiththeomnisysteminpatientswithopenangleglaucomatwoyearresultsfromtheromeostudy
AT voldstevend canaloplastyandtrabeculotomywiththeomnisysteminpatientswithopenangleglaucomatwoyearresultsfromtheromeostudy
AT campbellanita canaloplastyandtrabeculotomywiththeomnisysteminpatientswithopenangleglaucomatwoyearresultsfromtheromeostudy
AT hirschlouis canaloplastyandtrabeculotomywiththeomnisysteminpatientswithopenangleglaucomatwoyearresultsfromtheromeostudy
AT selvaduraideepan canaloplastyandtrabeculotomywiththeomnisysteminpatientswithopenangleglaucomatwoyearresultsfromtheromeostudy
AT aminlariardalane canaloplastyandtrabeculotomywiththeomnisysteminpatientswithopenangleglaucomatwoyearresultsfromtheromeostudy
AT cotliarjeremy canaloplastyandtrabeculotomywiththeomnisysteminpatientswithopenangleglaucomatwoyearresultsfromtheromeostudy
AT dickersonjaimee canaloplastyandtrabeculotomywiththeomnisysteminpatientswithopenangleglaucomatwoyearresultsfromtheromeostudy